A new drug for treating early-stage Alzheimer’s disease has been administered for the first time in Taiwan on an 83-year-old ...

The new medications are currently not covered by Taiwan’s health insurance system but are available to patients who can pay ...

The following six biosimilars were given a positive opinion at the June meeting: treatments for treatment of age-related macular degeneration and visual impairment: Mynzepli (aflibercept), and its ...

Biogen is an intriguing stock that occupies one of the leading positions in the central nervous system therapeutic market.

They are now facing the first direct competition to Leqembi from Eli Lilly's Kisunla (donanemab), which has been approved with a fixed duration of treatment until amyloid plaques in the brain resolve.

Since then, the launch of Leqembi and Kisunla has renewed interest in the anti-amyloid approach, although early take-up of the new drugs has been slow due to their modest efficacy and potential to ...